Eli Lilly and Company (NYSE: LLY) surpassed earnings expectations for the third quarter of 2019 but revenues came in shy of estimates. Shares fell over 3% in premarket hours on Wednesday.
Total revenue grew 3% year-over-year to $5.47 billion, but fell short of estimates of $5.5 billion. Revenues grew 4% excluding foreign currency impacts. Revenue growth was driven by an 8% increase in volume.
GAAP net income was $1.25 billion, or $1.37 per share, compared to $1.15 billion, or $1.12 per share, in the prior-year period. Adjusted net income increased 5% to $1.36 billion, while EPS increased 10% to $1.48. Analysts had forecast adjusted EPS of $1.40.
Revenue in the US remained relatively flat at $3 billion versus the prior-year period due to lower realized prices. Revenues outside the US rose 8% to $2.4 billion, driven by a volume growth of 12% mainly from key growth products like Trulicity, Jardiance and Taltz.
In the third quarter, the company recognized acquired in-process R&D charges of $77.7 million, related to the business development transactions with Centrexion Therapeutics Corporation and AC Immune SA.
During the quarter, Eli Lilly saw double-digit growth in revenues from Trulicity, Taltz, Basaglar, Cyramza and Jardiance. Cialis posted the highest decline in revenues of 61%.
Looking ahead, the company expects revenue growth to be driven by Trulicity, Taltz, Basaglar, Jardiance, Verzenio, Cyramza, Olumiant, and Emgality. Revenues are also expected to benefit from the recent launch of Baqsimi.
For the full year of 2019, revenue is expected to be $22 billion to $22.5 billion. GAAP EPS is expected to be $8.59-8.69 and adjusted EPS is expected to be $5.75-5.85.
After registering a slow recovery in the first half of the week, the markets pared these gains on Thursday and Friday. The weakness witnessed in the latter half of the
Illumina, Inc. (NASDAQ: ILMN), a pioneer in genome sequencing technology, has strived to strengthen its unique position in the healthcare sector through strategic partnerships and technological innovation. Its performance so
The COVID-19 pandemic raged through the first half of this year and continues to impact the world without signs of abating. Amid this health crisis, several companies reported strong results